Status: Recruiting
Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.
This is a prospective, phase 2, multicenter, open-label, single-arm study. Primary objective is to assess the efficacy of loncastuximab tesirine given as consolidation therapy after salvage immunochemotherapy in BTKi (Bruton Tyrosine Kinase inhibitors) -treated (or BTKi intolerant) R/R (Relapse or Refractory) MCL (Mantle Cell Lymphoma) patients. The sponsor of this clinical trial is Fondazione Italiana Linfomi - ETS (FIL ETS).
Participants needed: 49
Trial details
Phase: Phase 2Age: 18-79Biological sex: AllType: InterventionalSponsor: Fondazione Italiana Linfomi - ETSUpdated: Jan 5, 2026Locations: 21
Eligibility criteria
Histologically documented diagnosis of MCL as defined in the 2017 edition of the... [+18]
Subjects who have received a bendamustine containing regimen and relapsed less t... [+15]